Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Subscribe Now
/Free Sign Up
 0
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair Value See Undervalued Stocks
Close

Aclaris Therapeutics Inc (ACRS)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aclaris Therapeutics Inc's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1.210 +0.040    +3.42%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.210
-0.000
-0.000%
16:46:06 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 141,575
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.175 - 1.210
Aclaris Therapeutics Inc 1.210 +0.040 +3.42%

Aclaris Therapeutics Inc Company Profile

 
Get an in-depth profile of Aclaris Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

103

Equity Type

ORD

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Contact Information

Address 701 Lee Road Suite 103
Wayne, 19087
United States
Phone 484 324 7933
Fax -
Web www.aclaristx.com

Top Executives

Name Age Since Title
Neal S. Walker 54 2012 Co-Founder, President, Chairman & Interim CEO
Christopher P. Molineaux 58 2014 Lead Independent Director
Guy F. Webster - - Member of Advisory Board
Mark Bradshaw 71 - Member of Advisory Board
Leslie Baumann - - Member of Advisory Board
Pearl E. Grimes - - Member of Advisory Board
Klaus PJ Theobald 68 - Member of Advisory Board
Kenneth Beer - - Member of Advisory Board
William D. Humphries 58 2016 Independent Director
Anand Mehra 48 2014 Independent Director
James J. Leyden 83 - Member of Advisory Board
Andrew L. Ondo - - Member of Advisory Board
Vincent J. Milano 60 2020 Independent Director
James G. Krueger - 2020 Member of the Scientific Advisory Board
Andrew Newman Schiff 59 2017 Independent Director
Stanley B. Cohen - 2020 Member of the Scientific Advisory Board
Michael E. Weinblatt - 2020 Member of the Scientific Advisory Board
Maxine Gowen 66 2019 Independent Director
Marco Colonna - 2020 Member of the Scientific Advisory Board
Philip J. Mease - 2021 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ACRS Comments

Write your thoughts about Aclaris Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Luka Tsirekidze
Luka Tsirekidze Mar 06, 2023 11:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
7$ buy and 12$ stop this week
Reply
7 0
Report
Lucian Ghiran
Lucian Ghiran Jan 21, 2021 12:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Textbook pump and dump. "Pump and dump" (P&D) is a form of securities fraud that involves artificially inflating the price of an owned stock through false and misleading positive statements, in order to sell the cheaply purchased stock at a higher price. Once the operators of the scheme "dump" (sell) their overvalued shares, the price falls and investors lose their money.
Reply
4 1
Report
John Avenetti
John Avenetti Jan 21, 2021 12:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
based on the very wealthy berg that I know pushing this...it's absolutely a pump and dump.
Reply
0 0
Report
Devang Thaker
DTHAKER Jan 21, 2021 10:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
was up by 200%. What do you think now ? It's still holding $17 is a surprise. Not gonna hold here for long.
Reply
2 1
Report
Tom Daniel
Tom Daniel Jan 21, 2021 10:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why? Do you know anything about this company? The comments on this investing app are always remedial. Come to this app if you want CNN BS
Reply
0 0
Report
Thao Bui
Thao Bui Jan 20, 2021 12:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
17 tomorrow
Reply
1 0
Report
Param Khakh
Param Khakh Jan 20, 2021 9:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
should i buy this stock right know ???
Reply
0 3
Report
Param Khakh
Param Khakh Jan 20, 2021 9:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
should i buy this stock right know ???
Reply
0 3
Report
Mi iR
Mi iR Jan 19, 2021 3:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why that much up????
Reply
1 0
Report
Cookie Crumbler
Cookie Crumbler Jan 19, 2021 3:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Do your homework. Like a good citizen who pays back to his country daily, instead of expecting from it, be proactive, learn, research, be aware and educated - so when you come to invest, you make better decisions and not like those lousy losers who stormed the capitol - don't be a loser!
Reply
1 6
Report
Jan 19, 2021 11:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
😳
Reply
2 0
Report
Thao Bui
Thao Bui Jan 19, 2021 11:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
small company easy control the price by big shark
Reply
3 0
Report
Hassan Al-Doukhi
Hassan Al-Doukhi Jan 19, 2021 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I shorted this rocket, RIP my portfolio.
Reply
5 1
Report
Show previous replies (1)
Paul Bert
bostonbaked Jan 19, 2021 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mehmet Ozdemir  why
Reply
0 0
Report
Mehmet Ozdemir
Mehmet Ozdemir Jan 19, 2021 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Paul Bert  technic, gotta hit $21.25
Reply
1 1
Report
Mehmet Ozdemir
Mehmet Ozdemir Jan 19, 2021 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Paul Bert  i would not touch it now, it is all spec right now
Reply
0 0
Report
Mehmet Ozdemir
Mehmet Ozdemir Jan 19, 2021 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i have 400 of them on $16.20, already make $4000
Reply
0 0
Report
Hassan Al-Doukhi
Hassan Al-Doukhi Jan 19, 2021 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Paul Bert i didnt read the news and i thought it was one of those pump and dump, then i got all rock headed and got myself burned, i pulled out on 16 so im not at a total loss.
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Apple
Continue with Google
or
Sign up with Email